Iterum Therapeutics (ITRM) shares gained more than 36% in recent Friday trading after the company said the US Food and Drug Administration has approved its new drug application for Orlynvah as a treatment for uncomplicated urinary tract infections in women.
The approval was based on data from its clinical development program, including the results from two phase 3 trials where Orlynvah demonstrated "superiority" to other treatments, the company said.
Iterum said the approval marks the first indication for Orlynvah, making it the company's first FDA-approved product.
Price: 1.99, Change: +0.82, Percent Change: +70.09
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。